Plain-English translation of NCT05316467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a structured weight management program to megestrol acetate — a hormone medication commonly used to treat early-stage endometrial cancer — can improve treatment success rates in women who are overweight or obese. About 70–80% of women respond well to this medication alone, but 20–30% don't respond or take longer to recover. The study hypothesizes that weight loss combined with this treatment may help more women achieve complete remission and have better chances of becoming pregnant afterward.
Being overweight or obese is known to reduce how well this medication works and can lower pregnancy rates after treatment. Weight loss has been shown to improve metabolism and fertility in other contexts, so researchers want to see if combining weight management with this medication can increase remission rates and improve pregnancy outcomes for women who want to keep their uterus and have children.
You likely qualify if…
You likely don't qualify if…
You would take megestrol acetate (a hormone tablet) daily and also participate in a structured weight management program that includes dietary guidance, exercise, and behavioral coaching. The study will monitor your cancer response through imaging and blood work, track your weight loss progress, and follow your reproductive health. You would need to commit to regular follow-up appointments at Fudan University's Obstetrics and Gynecology Hospital and maintain good compliance with both the medication and the weight management program.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Xiaojun Chen
Enrollment target
~89 participants
Started
May 2022
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 45 Years
Sex
Female only
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
WEIWEI SHAN, PhD
Obstetrics & Gynecology Hospital of Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.